In THYM, the expression of RCC1 is not only negatively correlated with CAF, but also positively correlated with CD8+ T cell tumor infiltration, which may imply that targeted drugs designed for RCC1 can effectively assist immunotherapy against THYM. This evidence concerns the gene CD8A and neoplasm.